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Background: The aim of this study was to evaluate whether polymorphisms in the guanine nucleotide binding
(G protein), beta polypeptide 1 (GNB1) gene are associated with a rapid virological response (RVR) among HCV
genotype 1 (HCV-1) and 2 (HCV-2) infected patients receiving peginterferon plus ribavirin treatment (PEG-IFNα-RBV).
Methods: We analyzed the association between RVR to PEG-IFNα-RBV therapy and 4 tagging single nucleotide
polymorphisms (SNPs) of the GNB1 gene. This study included 265 HCV-1 and 195 HCV-2 infected patients in a
Chinese population in Taiwan.
Results: Among the GNB1 SNPs examined, the combination of genotypes G/G and G/T populations of rs12126768
was significant inversely correlated with RVR in HCV-1 infected patients (P = 0.0330), whereas HCV-2 infected
patients, combination of A/A and A/C genotypes populations at rs4648727 responded better to the PEG-IFNα-RBV
treatment (P = 0.0089). However, there were no significant differences in the allele frequencies of those SNPs
between RVR responders and non-responders. Several RVR susceptibility GNB1 haplotypes were identified, and the
ACAT haplotype of the 4 SNPs may increase the successful outcomes of HCV-1 and HCV-2 infected patients
(P = 0.0261 and P = 0.0253, respectively).
Conclusion: The data for GNB1 SNPs and the association of RVR showed that GNB1 polymorphisms might be
associated with the therapeutic outcomes of HCV-1 and HCV-2 infected patients under standard of care
(SOC) treatment.
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Chronic hepatitis C virus (HCV) infection remains a
major public health concern, with approximately 200 mil-
lion individuals, that is, 3% of the world population,
infected [1]. Only 20–30% of HCV infected people will re-
cover spontaneously, while the majority of infected popu-
lations with persistent infection may subsequently develop
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reproduction in any medium, provided the orcarcinomas (HCC) [2]. Therefore, successful treatment is
extremely important.
The standard of care (SOC) for HCV infection consisted
of pegylated interferon (PEG-IFN)-α 2a or 2b plus the nu-
cleotide analog, ribavirin (RBV) [3]. However, there are var-
iations in treatment outcome among different populations.
The genotype and viral load of HCV infected patients are 2
major factors that determine treatment outcome. Patients
infected with HCV genotype 2 and 3 (HCV-2/3) achieved
an 80% HCV eradication rate; however, only about 50% of
individuals infected with HCV genotype 1 (HCV-1) achieve
eradication [3]. Successful treatment, meaning no detectable
HCV RNA after 6 months of complete therapy, is termed as. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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treatment, a rapid virological response (RVR, HCV RNA
negative at week 4) is the strongest predictor of SVR [4].
Under SOC treatment, several significant differences in
therapeutic response due to ethnic effects have been
reported. HCV-1 infected Caucasian patients achieve a
better SVR rate than African American patients (40–52%
vs. 20–28%), while HCV-2/3 infected Caucasian patients
also achieve a better SVR rate than African Americans
patients (82% vs. 57%) [5,6]. Therefore, host genetic fac-
tors may play a role in the natural route of infection as
well as treatment outcome.
Several host genetic factors that may be associated with
the efficacy of IFN therapies have been reported, including
mannose-binding lectin (MBL) [7], myxovirus resistance
protein A (MxA) promoter [8], low-molecular-mass poly-
peptide 7 (LMP7) [9], apolipoprotein E4 [10], interleukin-
10 (IL-10) promoter [11], IFNα receptor 1 (IFNAR1) [12],
cytotoxic T-lymphocyte antigen 4 (CTLA4) [13], RANTES
[14], interleukin-12 (IL-12) [15], osteopontin (OPN) [16],
G protein β3 subunit (GNB3) [17], mitogen-activated pro-
tein kinase-activated protein kinase 3 (MAPKAPK3) [18],
and interleukin 28B (IL-28B) [19]. Although some of above
genes are indirectly correlated with the IFN pathway, the
involvement of polymorphisms in genes encoding compo-
nents of the chemokine system may significantly influence
treatment response, for example, the GNB3 gene.
G protein acts as a key regulator of several membrane-
mediated signal transduction cascades [20]. Different
kinds of signaling that trigger G protein activation lead to
dissociation of the trimeric form of G protein into the Gα
subunit and the Gβγ complex. Typically, the Gβγ subunits
cannot dissociate, except through non-denaturing condi-
tions [20]. The Gβγ subunits act as a functional unit that
controls numerous essential cell functions such as gene
activation and repression [21]. Although the interferon
signaling cascades do not directly transmit through het-
erotrimeric G proteins, in the course of treatment with
PEG-IFNα-RBV, release of multiple chemokines may in-
volve heptahelical receptors coupled to G proteins [22].
Therefore, polymorphisms in related G proteins could also
influence the signaling cascade in the treatment response.
In the present study, we investigated the association be-
tween single nucleotide polymorphisms (SNPs) in the
GNB1 gene and their susceptibility to RVR in Chinese
patients in Taiwan receiving PEG-IFNα-RBV treatment.
Our results support GNB1 as a potential candidate gene




In the present study, 265 HCV-1 infected patients and
195 HCV-2 infected patients at China Medical UniversityHospital, Taichung, Taiwan were enrolled and actively
observed. Diagnosis of HCV infection was based on per-
sistent elevation of serum transaminase levels for at least
6 months, serum anti-HCV-positivity, and consistent de-
tection of serum HCV RNA. Patients with hepatitis B sur-
face antigen and antibodies or human immunodeficiency
virus 1 and 2 positivity were excluded from this study.
The enrolled patients were subcutaneously injected with
PEG-IFNα (PEG-IFNα-2b, Peg-Intron, Schering-Plough,
Kenilworth, NJ, USA) at a dose of 1.5 μg/kg/week in com-
bination with weight-adapted doses of oral RBV (<60 kg,
800 mg/day; 60–75 kg, 1000 mg/day; and >75 kg, 1200
mg/day) for 48 weeks (HCV-1) or 24 weeks (HCV-2). All
subjects provided informed consent. The study protocol
was approved by the chairman of the Ethics Committee of
China Medical University Hospital, Taichung, Taiwan, and
was conducted in accordance with the Declaration of
Helsinki.SNP selection
Selection of representative GNB1 SNPs was based on SNP
genotype information downloaded in December 2008
from the HapMap Chinese Han in Beijing (CHB) + JPT
population. HapMap genotypes were further analyzed via
Haploview software (version 4.2). Tag SNPs were selected
using the Tagger function according to the following cri-
teria: (1) minor allele frequency (MAF) in the HapMap
CHB + JPT population >0.10, and (2) a ≥0.6 genotyping
score (recommended by the manufacturer, Illumina, Inc.,
San Diego, CA) to reach a successful genotyping rate.
Four SNPs in the GNB1 gene met these criteria and were
selected: rs10907185 (S1) (A/G in intron 7), rs6603797
(S2) (C/T in intron 2), rs4648727 (S3) (A/C in intron 1),
and rs12126768 (S4) (G/T in intron 1).HCV genotyping and RNA measurements
HCV genotyping according to the classification of Sim-
monds et al. [23] was performed by reverse hybridization
assay (INNO LiPA HCV-II; Innogenetics, Gent, Belgium).
Virologic response was assessed using a qualitative HCV
RNA assays with a low sensitivity of 30–50 IU/mL (HCV
Amplicor™ 2.0, Roche Diagnostics, Branchburg, NJ). All
HCV RNA level results are reported in copies/mL.
According to the qualitative HCV RNA results, patients
were defined as (1) rapid virological responders (RVRs,
HCV RNA negative at week 4 of treatment), denoted as
RVR (+), or (2) non-rapid virological responders (non-
RVRs, HCV RNA positive at week 4 of treatment),
denoted as RVR (−). The term “flat responder” refers to
the population that showed no variation in the HCV RNA
after receiving the SOC treatment. Flat responders were
not present among the patients enrolled in this study be-
cause the change in the HCV RNA was unique for each
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classified into the RVR (−) group. Therefore, all subjects
were classified as RVR (+) or RVR (−).Genomic DNA extraction and genotyping
Genomic DNA was isolated from the peripheral blood
of all participants by using a commercial kit (Genomic
DNA kit; QIAGEN, Valencia, CA) according to the man-
ufacturer’s instructions. All 4 SNPs in GNB1 were geno-
typed using an allele-specific extension method and
ligation assay according to the manufacturer’s instruc-
tions (Illumina, San Diego, CA).Statistical analysis
The association between each categories was assessed by
the χ2 test. Genotype and allele frequencies in RVR (+)
and RVR (−) subjects were compared, and odds ratios
(ORs) with 95% confidence intervals (CIs) were esti-
mated by unconditional logistic regression. Variables
such as age, body mass index (BMI), aspartate amino-
transferase (AST), alanine aminotransferase (ALT),
platelet (PLT), and viral load were estimated by the
Mann–Whitney U test. The differences among geno-
types and viral loads were estimated by the Kruskal–
Wallis test for multiple groups. All statistical analyses
were performed using SPSS version 20.0 for Windows
(Chicago, IL). Results with a P value less than 0.05
were considered statistically significant. Screening
and construction of linkage disequilibrium (LD)
plots were performed using Haploview (version 4.2).
Haplotype analysis with sliding windows and Hardy–
Weinberg equilibrium (HWE) was inferred using
PLINK (version 1.07; http://pngu.mgh.harvard.edu/
purcell/plink/) [24].Table 1 Characteristics of HCV genotype 1 and 2 infected pat
HCV genotype 1 (HCV-1)
Total RVR (+) RVR (−)
Number of patients 265 108 157
Sex (males/females) 129/136 55/53 74/83
Age (mean ± SD) 52.17 ± 10.27 50.96 ± 10.97 52.99 ± 9.71




Stage of fibrosis (F0/F1-4) 16/249 3/105 13/144
AST (U/L) (mean ± SD) 83.5 ± 57.1 80.7 ± 45.1
ALT (U/L) (mean ± SD) 132.2 ± 93.5 102.4 ± 57.6
PLT (×103/μl) (mean ± SD) 174.6 ± 62.3 163.7 ± 55.7
Viral load (× 106) 12.1 ± 16.4 7.0 ± 10.3 16.0 ± 18.8
Abbreviations: RVR, rapid virological response; BMI, body mass index; AST, aspartate
a Calculated by the Mann–Whitney U test.
b Calculated by the by χ2 test.Results
Patient characteristics
The characteristics and clinical information for the HCV
infected participants by HCV genotype are shown in
Table 1. A total of 265 HCV-1 infected patients and 195
HCV-2 infected patients were enrolled. The overall RVR
rates of HCV-1 and HCV-2 infected patients were 40.8%
and 81.0%, respectively. The distribution of the GNB1
phenotype among the sexes, age at study entry, BMI, de-
gree of inflammatory activity, and stage of fibrosis did
not differ significantly according to RVR (+/−) in the
HCV-1 and HCV-2 groups. However, viral load at the
start of treatment differed significantly between the RVR
(+) and RVR (−) patients in the HCV-1 group (P < 0.0001).
The viral loads of HCV-1 infected patients with rs10907185,
rs6603797, rs4648727, and rs12126768 genotypes did not
differ significantly (P = 0.270, P = 0.559, P = 0.952, and
P = 0.414, respectively).
All 4 GNB1 SNPs genotyped in this study were in
Hardy–Weinberg equilibrium (HWE) (P > 0.05). This
indicated that there was no population stratification bias
or genotyping error in our anticipated subjects. Informa-
tion on the SNPs, including chromosome position,
HWE, and minor allele frequencies (MAF) is listed in
Table 2.
Association between tagging SNPs of GNB1 and
therapeutic response, RVR
The genotype frequencies of each SNP showing respon-
siveness to PEG-IFNα-RBV therapy are shown in Table 3.
In the genotype association tests, none of the genotypes
was associated with RVR in HCV-1 infected patients
(Table 3). However, the combination of genotypes G/G
and G/T of rs12126768 was significantly inversely corre-
lated with RVR responsiveness (P = 0.0330, OR = 0.58,ients receiving PEG-IFNα-RBV therapy
HCV genotype 2 (HCV-2)
P value Total RVR (+) RVR (−) P value
- 195 158 37 -
0.545 88/107 75/83 13/24 0.176
0.172a 51.62 ± 10.89 51.08 ± 10.92 53.89 ± 10.62 0.095a
0.971a 24.5 ± 3.5 24.5 ± 3.7 24.5 ± 3.1 0.933a
0.115b 22/173 19/139 3/34 0.498 b
0.065 b 10/185 9/149 1/36 0.457 b
0.988 a 85.7 ± 65.5 75.2 ± 39.1 0.677 a
0.018 a 122.9 ± 108 101.9 ± 60.7 0.329 a
0.146 a 173.6 ± 53.5 155.5 ± 50.1 0.041 a
<0.0001a 11.0 ± 19.0 10.0 ± 18.2 15.3 ± 21.8 0.217a
aminotransferase; ALT, alanine aminotransferase; PLT, platelet.
Table 2 Four single nucleotide polymorphisms in the GNB1 gene in 265 HCV-1 and 195 HCV-2 infected patients






HWE (P value) MAF HWE (P value) MAF
RVR (+) RVR (−) RVR (+) RVR (−)
rs10907185 (S1) Intron 7 1733219 A/G 0.2132 0.3009 0.2548 0.465 0.2785 0.2162
rs6603797 (S2) Intron 2 1765583 C/T 0.5854 0.1065 0.1401 0.4007 0.0981 0.0946
rs4648727 (S3) Intron 1 1776269 A/C 0.1309 0.3241 0.3429 0.8709 0.3513 0.2361
rs12126768 (S4) Intron 1 1778090 G/T 0.7439 0.2083 0.2756 1 0.2373 0.2162
Abbreviations: SNP, single nucleotide polymorphism; HWE, Hardy–Weinberg equilibrium; MAF, minor allele frequency.
a Chromosome positions refer to the sequence in the NCBI database (build 37.3).
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polymorphism at position rs4648727 in the GNB1 gene
was statistically associated with RVR (P = 0.0194). For
the A/A + A/C versus C/C genotype, we calculated an
increased crude OR of 2.67 (95% CI = 1.26, 5.65;
P = 0.0089) for RVR (+) versus RVR (−). The association
of rs12126768 genotypes with RVR remained significant
in the HCV-2 infected group (P = 0.0436). Therefore,
HCV infected individuals with the GNB1 rs4648727 C/CTable 3 Genotype frequencies of GNB1 single nucleotide poly
receiving PEG-IFNα-RBV therapy with and without a RVR in a
HCV-1









A/A 10 (9.2) 5 (3.2) 3.09 (1.00, 9.56)
A/G 45 (41.7) 70 (44.6) 0.99 (0.60, 1.66)
G/G 53 (49.1) 82 (52.2) 0.1096 1
A/A + A/G 55 (50.9) 75 (47.8) 0.6137 1.13 (0.69, 1.85)
rs6603797
C/C 87 (80.5) 116 (73.9) 1.13 (0.18, 6.88)
C/T 19 (17.6) 38 (24.2) 0.75 (0.12, 4.88)
T/T 2 (1.9) 3 (1.9) 0.4332 1
C/C + C/T 106 (98.1) 154 (98.1) 0.9723 1.03 (0.17, 6.29)
rs4648727a
A/A 10 (9.3) 14 (9.0) 0.94 (0.38, 2.29)
A/C 50 (46.3) 79 (50.6) 0.83 (0.50, 1.39)
C/C 48 (44.4) 63 (40.4) 0.7779 1
A/A + A/C 60 (55.6) 93 (59.6) 0.5112 0.86 (0.52, 1.41)
rs12126768a
G/G 6 (5.5) 9 (5.8) 0.76 (0.26, 2.25)
G/T 33 (30.6) 68 (43.6) 0.56 (0.33, 0.94)
T/T 69 (63.9) 79 (50.6) 0.0891 1
G/G + G/T 39 (36.1) 77 (49.4) 0.0330* 0.58 (0.35, 0.96)
a: Contains 1 missing data point in the RVR (−) group.
Abbreviations: SNP, single nucleotide polymorphism; RVR, rapid virological response
Genotype frequencies were determined by χ2 test using 2 × 3 or 2 × 2 tables as ap
unconditional logistic regression. P values less than 0.05 were considered statisticaland rs12126768 G/G genotypes may be at increased risk
being non-responsive to PEG-IFNα-RBV treatment.
Although the distribution of some GNB1 genotypes
differed significantly between RVR (+) and RVR (−), the
distribution of the allele frequencies of the SNPs did not
differ significantly between these 2 groups (Table 4). We
subsequently stratified patients by gender and HCV
genotype (HCV-1 or HCV-2), and investigated GNB1
genotype-dependent treatment responses. Table 5morphisms (SNPs) in HCV-1 and HCV-2 infected patients
Chinese population in Taiwan
HCV-2









A/A 13 (8.3) 3 (8.1) 1.25 (0.33, 4.76)
A/G 62 (39.2) 10 (27.0) 1.79 (0.80, 4.02)
G/G 83 (52.5) 24 (64.9) 0.3601 1
A/A + A/G 75 (47.5) 13 (35.1) 0.1748 1.67 (0.79, 3.51)
rs6603797
C/C 129 (81.6) 31 (83.8) 2.08 (0.18, 23.69)
C/T 27 (17.1) 5 (13.5) 2.70 (0.20, 35.75)
T/T 2 (1.3) 1 (2.7) 0.7216 1
C/C + C/T 156 (98.7) 36 (97.3) 0.5227 2.17 (0.19, 24.55)
rs4648727a
A/A 16 (10.1) 4 (11.1) 1.46 (0.44, 4.83)
A/C 79 (50.0) 9 (25.0) 3.20 (1.39, 7.41)
C/C 63 (39.9) 23 (63.9) 0.0194* 1
A/A + A/C 95 (60.1) 13 (36.1) 0.0089* 2.67 (1.26, 5.65)
rs12126768
G/G 6 (3.8) 4 (10.8) 0.42 (0.11, 1.61)
G/T 63 (39.9) 8 (21.6) 2.21 (0.94, 5.22)
T/T 89 (56.3) 25 (67.6) 0.0436* 1
G/G + G/T 69 (43.7) 12 (32.4) 0.2118 1.62 (0.76, 3.44)
; OR, odds ratio; CI, confidence interval.
propriate. Odds ratios and 95% CI per genotype were estimated by
ly significant, and are denoted with an asterisk.
Table 4 Allele frequencies of GNB1 single nucleotide polymorphisms in HCV-1 and HCV-2 infected patients receiving
PEG-IFNα-RBV therapy with and without a RVR in a Chinese population in Taiwan
HCV-1 HCV-2

















A allele 65 (30.0) 80 (25.5) 1.26 (0.86, 1.85) A allele 88 (27.8) 16 (21.6) 1.40 (0.76, 2.56)
G allele 151 (70.0) 234 (74.5) 0.2416 1 G allele 228 (72.2) 58 (78.4) 0.2756 1
rs6603797 rs6603797
C allele 193 (89.4) 270 (86.0) 1.37 (0.80, 2.34) C allele 285 (90.2) 67 (90.5) 0.96 (0.41, 2.28)
T allele 23 (10.6) 44 (14.0) 0.2521 1 T allele 31 (9.8) 7 (9.5) 0.9270 1
rs4648727a rs4648727a
A allele 70 (32.4) 107 (34.3) 0.92 (0.64, 1.33) A allele 111 (35.1) 17 (23.6) 1.75 (0.97, 3.16)
C allele 146 (67.6) 205 (65.7) 0.6515 1 C allele 205 (64.9) 55 (76.4) 0.0607 1
rs12126768a rs12126768
G allele 45 (20.8) 86 (27.6) 0.69 (0.46, 1.04) G allele 75 (23.7) 16 (21.6) 1.13 (0.61, 2.08)
T allele 171 (79.2) 226 (72.4) 0.0783 1 T allele 241 (76.3) 58 (78.4) 0.6989 1
a: Contains 1 missing data point in the RVR (−) group.
Abbreviations: SNP, single nucleotide polymorphism; RVR, rapid virological response; OR, odds ratio; CI, confidence interval.
Allele frequencies were determined by χ2 test using 2 × 2 tables. Odds ratios and 95% CI per allele were estimated by unconditional logistic regression. P values
less than 0.05 were considered statistically significant.
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polymorphisms stratified by gender. The genotypes of
SNP rs4648727 and rs12126768 were significantly asso-
ciated with RVR in HCV-2 infected females (P = 0.0202
and P = 0.0350, respectively). However, no gender effects
were associated with genotype responsiveness in the
HCV-1 infected population. The allele frequencies of all
the SNPs did not differ significantly between the males
and females in either group (Table 6).
For LD analysis, our results indicated the existence of
a low degree of pairwise LD among these SNPs in HCV-1
and HCV-2 infected populations with or without RVR. A
graphical summary of the LDs (r2 values) among
the tested SNPs at different loci is shown in Figure 1. Four
tag SNPs were selected and designated in a sequential
order.
Frequencies of GNB1 haplotypes and their association
with RVR
We compared the haplotype frequencies and treatment
responses adjusting for gender as a covariate to avoid
potential confounding effects using the PLINK program
as shown in Table 7. Global analyses of haplotypes were
performed by sliding window mode to examine all the
possible sizes of the haplotypes (number of SNPs per
haplotype). We found that there were 10 sliding win-
dows, 2 of which were significantly associated with RVR
(omnibus test P < 0.05) in HCV-1 infected patients.
The overall global test, details, and haplotype frequen-
cies are listed in Table 8. In HCV-1 infected patients,
haplotype AC, the window S1-S2, gave the mostimpressive P value for the omnibus test. However, it did
not play a significant role in HCV-2 infected patients.
Haplotype-specific analyses showed that the CAT haplo-
types (S2-S3-S4) might increase the rate of RVR
(P = 0.0265; OR = 4.50) when compared to the RVR (−)
groups, especially in the HCV-2 infected population.
The window S1-S2-S3-S4 with the ACAT haplotypes
was significantly positively associated with a higher rate
of RVR in both HCV-1 and HCV-2 infected patients
(OR = 2.01, P = 0.0261 and OR = 4.54, P = 0.0253, re-
spectively). Furthermore, the results showed that HCV-1
and HCV-2 infected patients with therapeutic responses
had the ACAT haplotypes, and thus the ACAT haplo-
type appeared more frequently in RVR (+) patients than
in RVR (−) patients. Therefore, in HCV-1 or HCV-2
infected individuals, haplotype-specific analysis showed
that the haplotype ACAT (S1-S2-S3-S4) was associated
with an increase in the RVR rate. This observation sug-
gests that the haplotype ACAT may play a role in the re-
sponse to PEG-IFNα-RBV treatment.
Discussion
We examined the association between related genes and
the efficacy of SOC therapy and identified the GNB1
gene on chromosome 1 as a new candidate susceptibility
gene. In this study, we found that the SNPs rs4648727
and rs12126768 in the introns of GNB1 may be asso-
ciated with the rate of RVR to PEG-IFNα-RBV treat-
ment. In addition, we found that 1 GNB1 haplotype
(ACAT), which is a combination of the set of SNPs in
this gene, was statistically associated with RVR. Clinical
Table 5 Genotype frequencies of GNB1 single nucleotide polymorphisms stratified by gender in HCV-1 and HCV-2
infected patients receiving PEG-IFNα-RBV therapy with and without a RVR in a Chinese population in Taiwan
HCV-1 HCV-2














A/A 6 (10.9) 2 (2.8) 4.32 (0.81, 23.17) A/A 8 (10.7) 0 (0.0) -
A/G 24 (43.6) 36 (48.6) 0.96 (0.46, 1.98) A/G 27 (36.0) 6 (46.2) 0.79 (0.24, 2.60)
G/G 25 (45.5) 36 (48.6) 0.1600 1 G/G 40 (53.3) 7 (53.8) 0.4292 1
A/A + A/G 30 (54.5) 38 (51.4) 0.7193 1.14 (0.56, 2.29) A/A + A/G 35 (46.7) 6 (46.2) 0.9727 1.02 (0.31, 3.33)
Females Females
A/A 4 (7.6) 3 (3.6) 2.19 (0.46, 10.52) A/A 5 (6.0) 3 (12.5) 0.66 (0.14, 3.07)
A/G 21 (39.6) 34 (41.0) 1.01 (0.49, 2.08) A/G 35 (42.2) 4 (16.7) 3.46 (1.07, 11.22)
G/G 28 (52.8) 46 (55.4) 0.5986 1 G/G 43 (51.8) 17 (70.8) 0.0618 1
A/A + A/G 25 (47.2) 37 (44.6) 0.7673 1.11 (0.56, 2.22) A/A + A/G 40 (48.2) 7 (29.2) 0.0981 2.26 (0.85, 6.02)
rs6603797 rs6603797
Males Males
C/C 45 (81.8) 50 (67.6) - C/C 60 (80.0) 12 (92.3) -
C/T 9 (16.4) 24 (32.4) - C/T 15 (20.0) 1 (7.7) -
T/T 1 (1.8) 0 (0.0) 0.0672 1 T/T 0 (0.0) 0 (0.0) - 1
C/C + C/T 54 (98.2) 74 (100.0) 0.2442 - C/C + C/T 75 (100.0) 13 (100.0) - -
Females Females
C/C 42 (79.2) 66 (79.5) 1.91 (0.19, 18.97) C/C 69 (83.1) 19 (79.2) 1.82 (0.16, 21.12)
C/T 10 (18.9) 14 (16.9) 2.14 (0.19, 23.72) C/T 12 (14.5) 4 (16.6) 1.50 (0.11, 21.31)
T/T 1 (1.9) 3 (3.6) 0.8179 1 T/T 2 (2.4) 1 (4.2) 0.8601 1
C/C + C/T 52 (98.1) 80 (96.4) 0.5609 1.95 (0.20, 19.26) C/C + C/T 81 (97.6) 23 (95.8) 0.6461 1.76 (0.15, 20.30)
rs4648727 rs4648727
Males Malesa
A/A 4 (7.3) 5 (6.8) 1.20 (0.29, 5.02) A/A 9 (12.0) 0 (0.0) -
A/C 31 (56.4) 39 (52.7) 1.19 (0.57, 2.49) A/C 39 (52.0) 5 (41.7) 2.02 (0.58, 7.05)
C/C 20 (36.3) 30 (40.5) 0.8905 1 C/C 27 (36.0) 7 (58.3) 0.2255 1
A/A + A/C 35 (63.6) 44 (59.5) 0.6301 1.19 (0.58, 2.45) A/A + A/C 48 (64.0) 5 (41.7) 0.1410 2.49 (0.72, 8.61)
Femalesa Females
A/A 6 (11.4) 9 (11.0) 0.79 (0.25, 2.48) A/A 7 (8.4) 4 (16.7) 0.78 (0.20, 3.04)
A/C 19 (35.8) 40 (48.8) 0.56 (0.27, 1.18) A/C 40 (48.2) 4 (16.7) 4.44 (1.36, 14.53)
C/C 28 (52.8) 33 (40.2) 0.3067 1 C/C 36 (43.4) 16 (66.6) 0.0202* 1
A/A + A/C 25 (47.2) 49 (59.8) 0.1513 0.60 (0.30, 1.21) A/A + A/C 47 (56.6) 8 (33.3) 0.0443* 2.61 (1.01, 6.77)
rs12126768 rs12126768
Males Males
G/G 3 (5.5) 3 (4.1) 1.06 (0.20, 5.59) G/G 2 (2.7) 0 (0.0) -
G/T 17 (30.9) 34 (45.9) 0.53 (0.25, 1.11) G/T 31 (41.3) 4 (30.8) 1.66 (0.47, 5.89)
T/T 35 (63.6) 37 (50.0) 0.2244 1 T/T 42 (56.0) 9 (69.2) 0.6089 1
G/G + G/T 20 (36.4) 37 (50.0) 0.1230 0.57 (0.28, 1.17) G/G + G/T 33 (44.0) 4 (30.8) 0.3723 1.77 (0.50, 6.25)
Femalesa Females
G/G 3 (5.7) 6 (7.3) 0.62 (0.14, 2.65) G/G 4 (4.8) 4 (16.7) 0.34 (0.08, 1.52)
G/T 16 (30.2) 34 (41.5) 0.58 (0.28, 1.23) G/T 32 (38.6) 4 (16.7) 2.72 (0.83, 8.90)
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Table 5 Genotype frequencies of GNB1 single nucleotide polymorphisms stratified by gender in HCV-1 and HCV-2
infected patients receiving PEG-IFNα-RBV therapy with and without a RVR in a Chinese population in Taiwan
(Continued)
T/T 34 (64.1) 42 (51.2) 0.3339 1 T/T 47 (56.6) 16 (66.6) 0.0350* 1
G/G + G/T 19 (35.8) 40 (48.8) 0.1391 0.59 (0.29, 1.19) G/G + G/T 36 (43.4) 8 (33.4) 0.3786 1.53 (0.59, 3.97)
a: Contains 1 missing data point in the RVR (−) group.
Abbreviations: SNP, single nucleotide polymorphism; RVR, rapid virological response; OR, odds ratio; CI, confidence interval.
Genotype frequencies were determined by χ2 test using 2 × 3 or 2 × 2 tables as appropriate. Odds ratios and 95% CI per genotype were estimated by
unconditional logistic regression. P values less than 0.05 were considered statistically significant, and are denoted with an asterisk.
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http://www.biomedcentral.com/1471-230X/12/167association studies showed that the GNB1 haplotype
(ACAT) carriers were significantly associated with a
higher archived rate of RVR (OR in the range of 1.81–
4.54) in both HCV-1 and HCV-2 infected patients. This
finding led us to the hypothesis that the treatment re-
sponse to PEG-IFNα-RBV could, in part, be dependent
on GNB1. The genotypes of GNB1 were equallyTable 6 Allele frequencies of GNB1 single nucleotide polymor
patients receiving PEG-IFNα-RBV therapy with and without R
HCV-1








A allele 36 (32.7) 40 (27.0) 1.31 (0.77, 2.25)
G allele 74 (67.3) 108 (73.0) 0.3206 1
rs6603797
C allele 99 (90.0) 124 (83.8) 1.74 (0.81, 3.73)
T allele 11 (10.0) 24 (16.2) 0.1493 1
rs4648727
A allele 39 (35.5) 49 (33.1) 1.11 (0.66, 1.87)
C allele 71 (64.5) 99 (66.9) 0.6942 1
rs12126768
G allele 23 (20.9) 40 (27.0) 0.71 (0.40, 1.28)
T allele 87 (79.1) 108 (73.0) 0.2580 1
Females
rs10907185
A allele 29 (27.4) 40 (24.1) 1.19 (0.68, 2.07)
G allele 77 (72.6) 126 (75.9) 0.5465 1
rs6603797
C allele 94 (88.7) 146 (88.0) 1.07 (0.50, 2.30)
T allele 12 (11.3) 20 (12.0) 0.8559 1
rs4648727a
A allele 31 (29.2) 58 (35.4) 0.76 (0.45, 1.28)
C allele 75 (70.8) 106 (64.6) 0.2961 1
rs12126768a
G allele 22 (20.8) 46 (28.0) 0.67 (0.38, 1.20)
T allele 84 (79.2) 118 (72.0) 0.1776 1
a: Contains 1 missing data point in the RVR (−) group.
Abbreviations: SNP, single nucleotide polymorphism; RVR, rapid virological response
Allele frequencies were determined by the χ2 test using 2 × 2 tables. Odds ratios an
P values less than 0.05 were considered statistically significant.distributed in males and females, the viral load, age at
study entry, BMI, and others clinical data did not differ
significantly among the different genotypes in the
HCV-1 and HCV-2 infected populations. Therefore, it is
unlikely that specific GNB1 genotypes predispose indi-
viduals to infection with HCV-1 and HCV-2 or contri-
bute to spontaneous virus elimination.phisms stratified by gender in HCV-1- and HCV-2-infected
VR in a Chinese population in Taiwan
HCV-2







A allele 43 (28.7) 6 (23.1) 1.34 (0.50, 3.56)
G allele 107 (71.3) 20 (76.9) 0.5572 1
rs6603797
C allele 135 (90.0) 25 (96.2) 0.36 (0.05, 2.85)
T allele 15 (10.0) 1 (3.8) 0.3136 1
rs4648727a
A allele 57 (38.0) 5 (20.8) 2.33 (0.82, 6.58)
C allele 93 (62.0) 19 (79.2) 0.1030 1
rs12126768
G allele 35 (23.3) 4 (15.4) 1.67 (0.54, 5.18)
T allele 115 (76.7) 22 (84.6) 0.3676 1
rs10907185
A allele 45 (27.1) 10 (20.8) 1.41 (0.65, 3.07)
G allele 121 (72.9) 38 (79.2) 0.3809 1
rs6603797
C allele 150 (90.4) 42 (87.5) 1.34 (0.49, 3.64)
T allele 16 (9.6) 6 (12.5) 0.5653 1
rs4648727
A allele 54 (32.5) 12 (25.0) 1.45 (0.70, 3.00)
C allele 112 (67.5) 36 (75.0) 0.3198 1
rs12126768
G allele 40 (24.1) 12 (25.0) 0.95 (0.45, 2.00)
T allele 126 (75.9) 36 (75.0) 0.8977 1
; OR, odds ratio; CI, confidence interval.
d 95% CI per genotype were estimated by unconditional logistic regression.
Figure 1 Linkage disequilibrium plot of the analyzed SNPs in the GNB1 gene. The figure shows the output of a Haploview (version 4.2)
linkage disequilibrium plot where each square (r2 values written within the box correspond to r2 values × 100 as a linkage disequilibrium
measure range) represents a pairwise linkage disequilibrium relationship between the 2 SNPs. Darkest colored squares indicate high linkage
disequilibrium (r2 = 1); medium colored squares indicate r2 values between 0 and 1; and the lightest colored squares indicate low linkage
disequilibrium (r2 = 0). The figure depicts the linkage disequilibrium pattern in (A) all HCV genotype 1 (HCV-1) infected patients; (B) HCV-1
infected patients receiving SOC therapy with RVR (−); (C) HCV-1-infected patients receiving SOC therapy with RVR (+); (D) all HCV genotype 2
(HCV-2) infected patients; (E) HCV-2 infected patients receiving SOC therapy with RVR (−); (F) HCV-2 infected patients receiving SOC therapy with
RVR (+).
Table 7 Summary of exhaustive haplotype analyses
based on sex-adjusted omnibus tests for sliding windows
of all possible sizes across 4 GNB1 SNPs
Sliding window (SW) Most significant result
HCV Genotype
1 2 1 2
SNPs/SW No. of SW SW SW P value P value
1 4 - - - -
2 3 S1..S2 S3..S4 0.0208* 0.0546
3 2 S2..S4 S2..S4 0.0540 0.1099
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patients infected with HCV-1 have about a 50% (in
Caucasians) and 80% (in African Americans) probability
of a poor response toward PEG-IFNα-RBV treatment.
In our study, the overall RVR rates were less than 45%
and 85% in the HCV-1 and HCV-2 populations, re-
spectively. Therefore, reliable prediction of a non-viral
response in the beginning of treatment would avoid
side effects and reduce the cost of treatment. Al-
though, viral clearance has been strongly associated
with various clinical features, for example, gender, age
<40 years, low HCV RNA level before treatment, ab-
sence of liver cirrhosis, and HCV genotype 2/3 [25].
Many researchers are still focused on the identification
of host genetic factors that may be related to clinical
Table 8 Details of sex-adjusted haplotype frequency
analysis for 2-SNP, 3-SNP, and 4-SNP windows showing
the most significant results among all possible sliding
windows
HCV-1
Haplotypes RVR (+) RVR (−) OR P value
rs10907185-rs6603797 (S1-S2)
OMNIBUS - - - 0.0208*
AC 0.2 0.1158 1.91 0.0078*
rs6603797-rs4648727-rs12126768 (S2-S3-S4)
OMNIBUS - - - 0.054
CAT 0.1157 0.0673 1.81 0.0524
rs10907185-rs6603797-rs4648727-rs12126768 (S1-S2-S3-S4)
OMNIBUS - - - 0.0397*
ACAT 0.1163 0.0615 2.01 0.0261*
HCV-2
Haplotypes RVR (+) RVR (−) OR P value
rs4648727-rs12126768 (S3-S4)
OMNIBUS - - - 0.0546
AT 0.1139 0.0278 4.50 0.0265*
rs6603797-rs4648727-rs12126768 (S2-S3-S4)
OMNIBUS - - - 0.1099
CAT 0.1139 0.0278 4.50 0.0265*
rs10907185-rs6603797-rs4648727-rs12126768 (S1-S2-S3-S4)
OMNIBUS - - - 0.1585
ACAT 0.1149 0.0278 4.54 0.0253*
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infection.
Previous studies have shown that the 825T allele of
GNB3 and its associated haplotypes are predictors of
enhanced signal transduction via G proteins. The GNB3
825 C/C genotype is associated with non-response in
HCV-1 infected patients [17,26]. Although the heterotri-
meric transformation of G proteins is not directly
involved in the interferon-signaling pathway, PEG-IFNα-
RBV treatment, which may initiate multiple chemokine
responses, may involve heptahelical receptors coupled to
G proteins [22]. Therefore, polymorphism in genes en-
coding components of the chemokine system may be
related to treatment outcomes. In this study, the exact
mechanism by which GNB1 genotypes are associated
with decreased or increased G protein activation
remains to be determined.
Although several virological responses have been used
to predict SVR, on comparing the baseline characteris-
tics, we observed that RVR increased and remained a
strong predictor of SVR [27]. In the HCV-1 infected
population, the SVR rate were significantly higher in the
RVR (+) patients (89.8%) than in the RVR (−) patients
(10.2%). On the other hand, in the HCV-2 infected
population, the SVR rate was significantly higher in theRVR (+) group (94.3%) than in the RVR (−) group
(5.7%). However, we did not find a significant association
between GNB1 SNPs and SVR. To estimate the sample
sizes for this association test, which would ensure a
maximum power of 80% at P < 0.05, we calculated the
sample size by using the G*Power 3.1 software. In future
studies, we plan to enroll a total of >1000 patients.
Therefore, additional factors need to be incorporated
to ensure a high likelihood for discriminating the
patients with RVR who will achieve SVR from those who
will not.
In 2 previous GWAS studies, they concluded that
SNPs in or near the IL-28B gene strongly determined
the outcome of HCV therapy [19,28-30]. The most sig-
nificant SNP in their study groups was rs8099917, which
was associated with SVR in European and Japanese
patients. Interestingly, rs8099917 was not associated with
the response to PEG-IFNα-RBV therapy in HCV-2/3
infected patients. They proposed that, the contributions of
host genetic factors to HCV-2/3 clearance are relatively low
compared with the contributions of host genetic factors to
HCV-1 clearance because HCV-2/3 is more likely to be
eliminated by SOC therapy. Our results demonstrated that
the GNB1 haplotype (ACAT) was significantly associated
with a higher rate of RVR both in HCV-1 and HCV-2
infected populations. The significance of the genetic effect
of GNB1 in other ethnicities remains to be elucidated.
Although we did not analyze the functional effects of
these intronic SNPs on the G protein, they were asso-
ciated with SOC therapy outcome. Since the GNB1 gene
was weakly associated with therapeutic outcomes, the
linkage among these GNB1 polymorphisms and RVR/SVR
should be confirmed in future studies with larger enrolled
populations. The results of this study may provide novel in-
formation toward determining the exact response to PEG-
IFNα-RBV.Conclusion
In conclusion, this study provided evidence that the
GNB1 gene polymorphisms are related to RVR in HCV-1
and HCV-2 infected patients. Furthermore, we determined
that the GNB1 haplotype (ACAT) plays a role in the clinical
response. Therefore, we believe that GNB1 may play an im-
portant role in activating the antiviral response prior to
treatment.
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